30th March 2022 | Pharma Updates
Aleor Dermaceuticals is acquired by Alembic Pharma
Alembic Pharmaceuticals has acquired 40% of Aleor Dermaceuticals Ltd from its joint-venture partner Orbicular Pharmaceuticals Technologies Private Ltd, according to the company.
India has the 'lowest' 374 Covid-19 deaths per million people, as per WHO
According to the WHO, India has one of the “lowest” 374 Covid-19 deaths per million population when compared to similarly impacted countries such as the United States, Brazil, Russia, and Mexico.
In 2022, robotic-assisted surgery will pave the door for better kidney cancer treatment
Surgical Robots have given surgeons in the pelvis better access and capabilities during reconstruction surgeries of the prostate, urinary bladder, ureter, and other areas.
Cystic Fibrosis Foundation awarded Eloxx with a therapeutic development award
Eloxx Pharmaceuticals announced that it has received additional funding from the CF Foundation in the form of a Therapeutic Development Award of up to $15.9 million to support the ongoing ELX-02 clinical programme.
Zentalis Pharmaceuticals-Caris Life Sciences partenered to support clinical trials for the Wee1 inhibitor ZN-c3
Zentalis has made strategic partnership with Caris Life Sciences, a leading molecular science and technology firm focused on developing and delivering cutting-edge healthcare solutions.
'Stealth Omicron': BA.2 is presently the most common Covid version worldwide
The spread of a sub-variant of the highly transmissible Omicron variant of coronavirus has resulted in an increase in the number of cases in various parts of the world.
Mirvetuximab Soravtansine in Ovarian Cancer is awaiting FDA approval
FDA has accepted a biologics licence application for mirvetuximab soravtansine monotherapy in patients with platinum-resistant ovarian cancer.
FDA approval for Moderna's 2nd booster dose of COVID-19 vaccine, mRNA-1273
FDA for amending its emergency use authorization to allow people 50 and older to receive a second booster dose of COVID-19 vaccine (mRNA-1273) at the 50 g dose level.
FDA cautious about the potential benefits of an experimental ALS drug
After months of lobbying by patient groups, the FDA issued a negative review of a closely watched experimental treatment for the severe illness known as Lou Gehrig’s disease.
For Type 2 Diabetes, FDA approved 2.0 mg dose of semaglutide injection
For the treatment of individuals with type 2 diabetes, the FDA has approved a 2.0 mg dose of semaglutide as a once-weekly subcutaneous injection.
For Type 2 Diabetes, FDA approved 2.0 mg dose of semaglutide injection
For the treatment of individuals with type 2 diabetes, the FDA has approved a 2.0 mg dose of semaglutide as a once-weekly subcutaneous injection.
